InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

InteRNA Technologies , a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Companys Supervisory Board.